Quantitative electroencephalography within sleep/wake states differentiates GABA A modulators eszopiclone and zolpidem from dual orexin receptor antagonists in rats

Neuropsychopharmacology

Volumn 38, Issue 12, 2013, Pages 2401-2408

  Fox, Steven V ^a   Gotter, Anthony L ^a   Tye, Spencer J ^a   Garson, Susan L ^a   Savitz, Alan T ^a   Uslaner, Jason M ^a   Brunner, Joseph I ^a   Tannenbaum, Pamela L ^a   McDonald, Terrence P ^a   Hodgson, Robert ^a   Yao, Lihang ^a   Bowlby, Mark R ^a   Kuduk, Scott D ^a   Coleman, Paul J ^a   Hargreaves, Richard ^a   Winrow, Christopher J ^a   Renger, John J ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

dual orexin receptor antagonist; EEG; eszopiclone; GABAA; spectral analysis; zolpidem

Indexed keywords

ESZOPICLONE; FILOREXANT; ZOLPIDEM;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG MEGADOSE; ELECTROENCEPHALOGRAM; ELECTROENCEPHALOGRAPHY; ELECTROMYOGRAM; FREQUENCY ANALYSIS; LOCOMOTION; LOW DRUG DOSE; MUSCLE TONE; NECK MUSCLE; NERVE CELL NETWORK; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RAT; REM SLEEP; SLEEP; SLEEP STAGE; SLEEP WAKING CYCLE; SOMNOLENCE;

ANIMALS; AZABICYCLO COMPOUNDS; BRAIN; ELECTROENCEPHALOGRAPHY; GABA-A RECEPTOR AGONISTS; MALE; OREXIN RECEPTORS; PIPERAZINES; PIPERIDINES; PYRIDINES; RATS; RATS, SPRAGUE-DAWLEY; SLEEP STAGES; TRIAZOLES;

EID: 84888391812     PISSN: 0893133X     EISSN: 1740634X     Source Type: Journal    
DOI: 10.1038/npp.2013.139     Document Type: Article

References (32)

1. Achermann P, Borbely AA (1987). Dynamics of EEG slow wave activity during physiological sleep and after administration of benzodiazepine hypnotics. Hum Neurobiol 6: 203-210. (Pubitemid 18071342)
2. Aeschbach D, Dijk DJ, Trachsel L, Brunner DP, Borbely AA (1994). Dynamics of slow-wave activity and spindle frequency activity in the human sleep EEG: effect of midazolam and zopiclone. Neuropsychopharmacology 11: 237-244. (Pubitemid 24372812)
3. Bettica P, Squassante L, Groeger JA, Gennery B, Winsky-Sommerer R, Dijk DJ (2012a). Differential effects of a dual orexin receptor antagonist (SB-649868) and zolpidem on sleep initiation and consolidation, SWS, REM sleep, and EEG power spectra in a model of situational insomnia. Neuropsychopharmacology 37: 1224-1233.
4. Bettica P, Squassante L, Groeger JA, Gennery B, Winsky-Sommerer R, Dijk DJ (2012b). Differential effects of a dual orexin receptor antagonist (SB-649868) and zolpidem on sleep initiation and consolidation, SWS, REM sleep, and EEG power spectra in a model of situational insomnia. Neuropsychopharmacology 37: 1224-1233.
5. Brisbare-Roch C, Dingemanse J, Koberstein R, Hoever P, Aissaoui H, Flores S et al (2007). Promotion of sleep by targeting the orexin system in rats, dogs and humans. Nat Med 13: 150-155.
6. Brunner DP, Dijk DJ, Munch M, Borbely AA (1991). Effect of zolpidem on sleep and sleep EEG spectra in healthy young men. Psychopharmacology (Berl) 104: 1-5.
7. Coleman PJ, Schreier JD, Cox CD, Breslin MJ, Whitman DB, Bogusky MJ et al (2012). Discovery of [(2R,5R)-5-{[(5-fluoropyridin-2-yl)oxy]methyl}-2- methylpiperidin-1-yl][5-methyl-2-(pyrimidin-2-yl)phenyl]methanone (MK-6096): a dual orexin receptor antagonist with potent sleep-promoting properties. Chem Med Chem 7: 415-424 337.
8. Cox CD, Breslin MJ, Whitman DB, Schreier JD, McGaughey GB, Bogusky MJ et al (2010). Discovery of the dual orexin receptor antagonist [(7R)-4-(5-chloro-1, 3-benzoxazol-2-yl)-7-methyl-1,4-diazepan-1-yl][5-methyl-2-(2H-1,2, 3-triazol-2-yl)phenyl]methanone (MK-4305) for the treatment of insomnia. J Med Chem 53: 5320-5332.
9. Desarnaud F, Murillo-Rodriguez E, Lin L, Xu M, Gerashchenko D, Shiromani SN et al (2004). The diurnal rhythm of hypocretin in young and old F344 rats. Sleep 27: 851-856. (Pubitemid 39095716)
10. Espa F, Ondze B, Deglise P, Billiard M, Besset A (2000). Sleep architecture, slow wave activity, and sleep spindles in adult patients with sleepwalking and sleep terrors. Clin Neurophysiol 111: 929-939. (Pubitemid 30236441)
11. Feige B, Voderholzer U, Riemann D, Hohagen F, Berger M (1999). Independent sleep EEG slow-wave and spindle band dynamics associated with 4 weeks of continuous application of shorthalf-life hypnotics in healthy subjects. Clin Neurophysiol 110: 1965-1974. (Pubitemid 29454626)
12. Gotter AL, Webber AL, Coleman PJ, Renger JJ, Winrow CJ (2012). International Union of Basic and Clinical Pharmacology. LXXXVI. Orexin receptor function, nomenclature and pharmacology. Pharmacol Rev 64: 389-420.
13. Herring WJ, Snyder E, Budd K, Hutzelmann J, Snavely D, Liu K et al (2012). Orexin receptor antagonism for treatment of insomnia: a randomized clinical trial of suvorexant. Neurology 79: 2265-2274.
14. Hindmarch I, Legangneux E, Stanley N, Emegbo S, Dawson J (2006). A double-blind, placebo-controlled investigation of the residual psychomotor and cognitive effects of zolpidem-MR in healthy elderly volunteers. Br J Clin Pharmacol 62: 538-545. (Pubitemid 44571574)
15. Hoque R, Chesson AL Jr (2009). Zolpidem-induced sleepwalking, sleep related eating disorder, and sleep-driving: fluorine-18-flourodeoxyglucose positron emission tomography analysis, and a literature review of other unexpected clinical effects of zolpidem. J Clin Sleep Med 5: 471-476.
16. Karni A, Tanne D, Rubenstein BS, Askenasy JJ, Sagi D (1994). Dependence on REM sleep of overnight improvement of a perceptual skill. Science 265: 679-682. (Pubitemid 24268282)
17. Kiyashchenko LI, Mileykovskiy BY, Maidment N, Lam HA, Wu MF, John J et al (2002). Release of hypocretin (orexin) during waking and sleep states. J Neurosci 22: 5282-5286. (Pubitemid 35386448)
18. Krystal AD, Edinger JD, Wohlgemuth WK, Marsh GR (2002). NREM sleep EEG frequency spectral correlates of sleep complaints in primary insomnia subtypes. Sleep 25: 630-640. (Pubitemid 34977502)
19. Landolt HP, Finelli LA, Roth C, Buck A, Achermann P, Borbely AA (2000). Zolpidem and sleep deprivation: different effect on EEG power spectra. J Sleep Res 9: 175-183. (Pubitemid 30333151)
20. Lundahl J, Deacon S, Maurice D, Staner L (2012). EEG spectral power density profiles during NREM sleep for gaboxadol and zolpidem in patients with primary insomnia. J Psychopharmacol 26: 1081-1087.
21. Martinez GS, Smale L, Nunez AA (2002). Diurnal and nocturnal rodents show rhythms in orexinergic neurons. Brain Res 955: 1-7. (Pubitemid 35284829)
22. Mintzer MZ, Frey JM, Yingling JE, Griffiths RR (1997). Triazolam and zolpidem: a comparison of their psychomotor, cognitive, and subjective effects in healthy volunteers. Behav Pharmacol 8: 561-574. (Pubitemid 27504706)
23. Ohayon MM (2002). Epidemiology of insomnia: what we know and what we still need to learn. Sleep Med Rev 6: 97-111. (Pubitemid 35231066)
24. Otmani S, Demazieres A, Staner C, Jacob N, Nir T, Zisapel N et al (2008). Effects of prolonged-release melatonin, zolpidem, and their combination on psychomotor functions, memory recall, and driving skills in healthy middle aged and elderly volunteers. Hum Psychopharmacol 23: 693-705.
25. Renger JJ, Dunn SL, Motzel SL, Johnson C, Koblan KS (2004). Sub-chronic administration of zolpidem affects modifications to rat sleep architecture. Brain Res 1010: 45-54. (Pubitemid 38569851)
26. Rush CR, Armstrong DL, Ali JA, Pazzaglia PJ (1998). Benzodiazepine- receptor ligands in humans: acute performanceimpairing, subject-rated and observer-rated effects. J Clin Psychopharmacol 18: 154-165.
27. Saper CB, Scammell TE, Lu J (2005). Hypothalamic regulation of sleep and circadian rhythms. Nature 437: 1257-1263. (Pubitemid 41568665)
28. Smith CT, Nixon MR, Nader RS (2004). Posttraining increases in REM sleep intensity implicate REM sleep in memory processing and provide a biological marker of learning potential. Learn Mem 11: 714-719. (Pubitemid 39602509)
29. Spiegelhalder K, Regen W, Feige B, Holz J, Piosczyk H, Baglioni C et al (2012). Increased EEG sigma and beta power during NREM sleep in primary insomnia. Biol Psychol 91: 329-333.
30. Trachsel L, Dijk DJ, Brunner DP, Klene C, Borbely AA (1990). Effect of zopiclone and midazolam on sleep and EEG spectra in a phase-advanced sleep schedule. Neuropsychopharmacology 3: 11-18. (Pubitemid 20077391)
31. Winrow CJ, Gotter AL, Cox CD, Doran SM, Tannenbaum PL, Breslin MJ et al (2011). Promotion of sleep by suvorexant-a novel dual orexin receptor antagonist. J Neurogenet 25: 52-61.
32. Winrow CJ, Gotter AL, Cox CD, Tannenbaum PL, Garson SL, Doran SM et al (2012). Pharmacological characterization of MK-6096-a dual orexin receptor antagonist for insomnia. Neuropharmacology 62: 978-987.